1.7 billion, another billion! That's what immunotherapy is all about

Source: biological exploration January 9, 2017, according to reports from several foreign websites, pharmaceutical giant Amgen announced to cooperate with imaging biotechnology to develop the next generation of dual-specific immunotherapy for multiple cancers This cooperation is expected to bring more than US $1 billion to imatics Specifically, Amgen agreed to make a $30 million down payment to imatics Imatics is also likely to receive more than $500 million in R & D, regulatory and commercial milestone payments and sales share from each project This cooperation will develop new anti-tumor drugs by combining the xpressident platform of imatics and the bite technology of Amgen The two companies concluded that their approach would allow each T cell to become activated and attack the tumor In the field of bispecific antibody, Amgen is in the leading position in the world In 2014, FDA has approved the listing of its bispecific antibody blincyto (Bluetooth, targeting CD19 and CD3) based on bite technology for the treatment of Philadelphia chromosome negative (pH -) recurrent / refractory precursor B-cell acute lymphoblastic leukemia In addition to the listed blincyto, there are three other bispecific antibodies in the clinical pipeline of amjin: AMG 211 (anti CEA, anti-CD3, for a variety of cancer types), AMG 330 (anti-CD33, anti-CD3, for acute myeloid leukemia), AMG 420 (anti BCMA, anti-CD3, for multiple myeloma) At present, these candidate drugs are in the phase I test phase Dr Sean E Harper, vice president of research and development of Amgen, said: "the intersection of immunology and oncology has produced a promising and rapidly developing treatment approach This has a profound impact on cancer patients We hope that our collaboration with imatics will transform its unique target and TCR discovery capabilities and Amgen's proven bite technology into new therapies " Immatics, headquartered in Germany, is a biopharmaceutical company dedicated to the development of cancer immunotherapy Long before it was chosen, the company had reached a deal worth more than $1 billion with another giant, Roche The transaction took place in 2013 Roche agreed to make a down payment of US $17 million to imatics The following is the product line of imatics: in the near future, there are frequent transactions in the field of bispecific immunotherapy Last week, French pharmaceutical giant Servier plans to work with Pieris pharmaceuticals to develop its preclinical dual checkpoint inhibitors (prs-332) and up to seven other immunooncology dual specific candidates The partnership will generate up to 1.7 billion euros ($1.8 billion) in revenue for Pieris pharmaceuticals In addition, at the end of last year, Incyte, which entered into a PD-1 antibody transaction with Hengrui, entered into a global strategic cooperation with merus to develop bispecific antibodies using the latter's biconics technology platform Incyte will pay a $120 million down payment to merus and a $80 million equity investment to acquire exclusive rights to up to 11 bispecific antibody projects.